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Abstract 
Aim: The aim of the audit was to determine 
whether the cardiovascular risk assessment and 
management in rheumatoid arthritis patients at Mater 
Dei Hospital is in concordance with the 
recommendations by the European League Against 
Rheumatism (EULAR). 
Background: Patients who suffer from rheumatoid 
arthritis have an increased risk of morbidity and 
mortality from cardiovascular disease. This is due to 
both the high prevalence of traditional risk factors, and 
systemic inflammation. 
Method: This audit was carried out retrospectively 
on 91 patients by using the medical notes to collect data 
on demographics, co-morbidities, drug history and 
cardiovascular risk assessment and management over a 
two year period (August 2010 to July 2012). The data 
was then analysed in order to assess whether the 
management of cardiovascular risk in rheumatoid 
arthritis patients was in concordance with EULAR 
recommendations. 
Results:  Cardiovascular risk factors were 
documented as follows over the two year period audited: 
weight in 27.5%, BMI in 0%, smoking status in 72.5%, 
blood pressure in 72.5%, blood glucose in 72.5% and 
lipid profile in 54.9%. Smoking cessation advice was 
given in 15.8% and advice on other lifestyle changes in 
14.3%. 81.1% of hypertensive patients were on 
treatment recommended as first-line by the guidelines 
and HbA1c was adequately controlled in 85.7% of 
diabetic patients in whom it was monitored.  
Conclusion: Cardiovascular risk factors are highly 
prevalent in rheumatoid arthritis patients. This audit 
identified aspects of cardiovascular risk assessment that 
require improvement. This would enable a better 
identification of cardiovascular risk factors that could be 
treated in order to reduce the patients’ cardiovascular 
morbidity and mortality. 
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Aims and Objectives 
The aim of the audit was to determine whether 
cardiovascular risk assessment and management is being 
carried out in rheumatoid arthritis patients at Mater Dei 
Hospital in concordance with the “EULAR evidence-
based recommendations for cardiovascular risk 
management in patients with rheumatoid arthritis and 
other forms of inflammatory arthritis” published in 
2010.1 A further aim was to identify whether the 
rheumatoid arthritis disease activity is adequately 
controlled. 
Moreover, the prevalence of the traditional risk 
factors (including diabetes, hypertension, 
hyperlipidaemia and smoking) in our cohort of Maltese 
rheumatoid arthritis patients was determined.  
 
Background 
Rheumatoid arthritis is a chronic systemic 
inflammatory disease that typically presents with a 
symmetrical polyarthritis with occasional extra-articular 
involvement of other systems including the skin, heart, 
lungs and eyes. The aetiology is unknown and the 
prevalence is approximately 1%. Women are affected 
approximately three times more often than men. 
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Patients with rheumatoid arthritis have multiple co-
morbidities of which cardiovascular disease is the most 
important. Studies have shown that rheumatoid arthritis 
patients have a markedly increased risk of death 
compared with the general population.2  This is largely 
due to the increased risk of ischaemic heart disease and 
cardiovascular death.3-5 Solomon et al observed an 
approximate doubling of the rate of myocardial 
infarction and stroke in patients with rheumatoid 
arthritis and the rate of cardiovascular death was 
increased by 30%.6  Moreover, a meta-analysis of 
fourteen controlled observational studies showed that the 
risk of incident cardiovascular disease is increased by 
48% in patients with rheumatoid arthritis compared to 
the general population.7 A cross-sectional study, the 
CARRE investigation, showed that the prevalence of 
cardiovascular disease in rheumatoid arthritis is 
increased to an extent that is at least comparable to that 
of type 2 diabetes.8 
A cross-sectional study on 400 rheumatoid arthritis 
patients showed that hypertension is highly prevalent 
(70%) in rheumatoid arthritis patients. In this study, it 
was noted that hypertension is under-diagnosed 
especially in young patients, and under-treated in older 
patients who have multiple co-morbdities.9 Moreover, an 
adverse lipid profile (lower high density lipoprotein 
cholesterol (C-HDL), apolipoprotein A1 and B and 
higher total cholesterol (CT) to C-HDL ratio and low 
density lipoprotein cholesterol (C-LDL) to C-HDL ratio) 
has been noted in rheumatoid arthritis patients when 
compared to the general population.10 
The excess cardiovascular burden cannot be fully 
explained by traditional cardiovascular risk factors 
alone. Systemic inflammation in rheumatoid arthritis 
contributes to the risk of cardiovascular events.11-14 
Current evidence shows that both the traditional risk 
factors and markers of rheumatoid arthritis severity 
contribute to cardiovascular risk.15-17 Thus screening and 
management of traditional cardiovascular risk factors as 
well as adequate control of inflammatory arthritis are 
necessary to prevent cardiovascular events in 
rheumatoid arthritis patients.18 
The EULAR guidelines make the following main 
recommendations, which we have used as gold standards 
for the audit: 
1. An annual cardiovascular risk assessment including 
measurement of blood pressure and random lipids is 
advised in rheumatoid arthritis patients. The 
SCORE model should then be used to determine the 
degree of cardiovascular risk. (Figure 1) This is an 
easy-to-use chart that helps calculate the ten year 
risk of fatal cardiovascular disease by taking into 
account traditional risk factors including age, 
gender, smoking, systolic blood pressure and 
cholesterol level.19 The EULAR guidelines 
recommend the use of the total cholesterol/HDL 
ratio when the SCORE model is used. Moreover, 
the risk should be multiplied by 1.5 if the patient 
has 2 of the following 3 criteria: a) disease duration 
of more than ten years, b) positive rheumatoid 
factor (RF) or anti-citrullinated protein antibodies 
(ACPA), c) presence of severe extra-articular 
manifestations. In patients with low cardiovascular 
risk and inactive disease, a lower frequency of 
assessment such as every 2-3 years could be 
adopted.  
2. Intervention should be carried out using local 
guidelines or if unavailable using the SCORE 
model. Cardioprotective treatment should be 
initiated when the estimated 10-year cardiovascular 
risk is above the risk threshold for each country. 
Since there are no local guidelines on the subject, 
the SCORE model and the “European guidelines on 
cardiovascular disease prevention in clinical 
practice” published in 2012 have been used for our 
purpose. These recommend that cholesterol-
lowering therapy should be started if cardiovascular 
risk is >5 to <10% and LDL is 2.5mmol/L or if 
cardiovascular risk is 10% and LDL is 
1.8mmol/L.20 
3. Statins, angiotensin converting enzyme (ACE) 
inhibitors and angiotensin II receptor blockers 
(ARBs) are preferred treatment options when 
indicated.  
4. Disease activity should be controlled adequately to 
further lower the cardiovascular risk. 
5. Smoking cessation should be recommended. 
6. Lifestyle modification advice should be given to all 
patients. 
 
Since there is no mention on the ideal targets for the 
control of diabetes by the EULAR guidelines, the 
recommendations by the “European guidelines on 
cardiovascular disease prevention in clinical practice” 
have been used as a gold standard in the audit.20 These 
recommend that the target HbA1c for the prevention of 
cardiovascular disease in diabetes is <7%. 
 
Method 
91 consecutive patients with definite rheumatoid 
arthritis according to the 2010 ACR/EULAR 
Rheumatoid Arthritis classification criteria were 
recruited from the database of patients under the care of 
a medical consultant.21 For every patient a proforma was 
completed using the medical notes, as well as the I-soft 
programme to collect the results of the blood 
investigations. 
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Figure1: The SCORE model used to calculate the ten year risk of fatal cardiovascular disease.19 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The data collected included basic information such 
as demographic data, past medical history of ischaemic 
heart disease and its traditional risk factors, drug history 
and smoking history. Data on cardiovascular risk 
assessment (including measurement of blood pressure, 
lipid profile, blood glucose) over a one year period 
(from August 2011 to July 2012) was also collected. If 
such data was absent since it was not measured or not 
documented, data from the previous one year period 
(August 2010 to July 2011) was collected if available. In 
those cases where data on age, gender, smoking, blood 
pressure and lipid profile was complete, the 10 year risk 
of fatal cardiovascular disease was calculated by using 
the SCORE chart. The total cholesterol/HDL ratio was 
used as a measure of cholesterol in the SCORE chart as 
advised by the EULAR guidelines. Moreover the risk 
was multiplied by 1.5 if the patient had 2 of the 3 
criteria: a) disease duration of more than ten years, b) 
positive RF or ACPA, c) presence of severe extra-
articular manifestations. The data was then analysed in 
order to determine whether cardiovascular risk 
management was being carried out as recommended by 
the guidelines. Thus it was determined whether 
hypertensive patients were being treated with ACE 
inhibitors or ARBs when indicated; whether 
hyperlipidaemic patients were being treated with statins 
when recommended; whether smoking cessation and 
lifestyle advice was being given and documented; 
whether DAS28, ESR and CRP were being measured 
and if disease activity was adequately controlled. 
Approval to carry out this audit was obtained by the 
data protection department at Mater Dei Hospital and by 
the University Research Ethics committee. 
 
Results 
Of the 91 patients audited 59 (64.8%) were female 
and 32 (35.2%) were male. The mean age was 62.7 
years. The duration of rheumatoid arthritis was 
documented in 79 patients (86.8%). The mean duration 
was 7.6 years. Rheumatoid factor result was documented 
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in 82 patients (90.1%), of which 62 patients (75.6%) 
were rheumatoid factor positive. ACPA result was 
documented in 48 patients (52.7%), of which 29 patients 
(60.4%) were ACPA positive. 
The patients’ weight was documented in 25 patients 
(27.5%). The height and BMI was not documented in 
any of the patients audited. The patients’ smoking status 
was documented in 66 patients (72.5%). Of these 19 
were smokers, 11 were ex-smokers and 36 were lifelong 
non-smokers. Out of the 19 current smokers, smoking 
cessation advice was given and documented in 3 patients 
(15.8%). In all the patients audited, lifestyle changes 
advice (including diet, exercise and weight loss) was 
given and documented in 13 patients (14.3%). 
The blood pressure was checked and documented at 
least once in the one year audited in 49 patients (53.8%). 
It was checked in the two year period in 66 patients 
(72.5%). Out of the patients audited, 37 suffered from 
hypertension. Of these, 23 patients were on an ACE 
inhibitor and 7 were on an angiotensin receptor blocker 
(ARB). Overall 81.1% of hypertensive patients were on 
an ACE inhibitor or ARB. 
Random or fasting blood glucose was measured in 
the previous year in 52 patients (57.1%). It was checked 
in the previous two years in 66 patients (72.5%). Out of 
the patients audited, 15 were diabetic. Of these HbA1c 
was checked in 7 patients (46.7%) over the two year 
period audited. This was 7% or more in only one patient. 
Out of the patients audited, 12 were known to suffer 
from hyperlipidaemia. Lipid profile was monitored in 35 
patients (38.5%) in the previous year and in 50 patients 
(54.9%) in the previous two years. The ten year 
cardiovascular risk could be calculated in 29 patients 
(31.9%) since these had complete data with regards to 
age, sex, smoking history, blood pressure and lipid 
profile. Eight of these patients were on a statin. When 
taking into account the cardiovascular risk and the last 
lipid profile, statins were indicated according to the 
guidelines in 5 out of these 29 patients; only one of these 
5 patients was on a statin. Statins were most likely also 
indicated in the remaining 7 patients on statins, since the 
lipid profile used to calculate the ten year cardiovascular 
risk was one taken over the last two years when the 
patient was already receiving a statin. 
 An ESR was checked in the previous year in 87 
patients (95.6%) and it was checked in the previous 2 
years in all patients. The CRP was checked in the 
previous year in 84 patients (92.3%) and it was checked 
in the previous two years in 89 patients (97.8%). DAS 
28 was calculated in the previous year in 19 patients 
(20.9%) and in the previous two years in 39 patients 
(42.9%). Out of these 39 patients, a high disease activity 
was noted in 5 patients; a moderate disease activity in 18 
patients; a low disease activity in 7 patients; and 9 
patients were in remission. 
 
Conclusions 
The prevalence of diagnosed hypertension in our 
cohort of rheumatoid arthritis patients was 40.7%; 
diabetes was 16.5%; hyperlipidaemia was 13.2%; and 
ischaemic heart disease was 6.6%. The prevalence of 
hypertension in the Maltese general population over 15 
years of age has been estimated to be 22%; while that of 
diabetes is 8%.22 This shows that the traditional risk 
factors for cardiovascular disease are highly prevalent 
and their monitoring and treatment is essential in order 
to decrease the mortality of rheumatoid arthritis patients. 
An improvement in the measurement of weight and 
height, and the calculation of BMI would be useful since 
it would prompt advice on weight loss, diet and exercise. 
Moreover the documentation of smoking status would 
encourage giving smoking cessation advice to smokers. 
The measurement of the traditional risk factors 
requires improvement. Blood pressure was measured in 
53.8%, blood glucose in 57.1% and lipid profile in 
38.5% over a one year period. This improved to 72.5%, 
72.5% and 54.9% respectively when a two year period 
was considered. Of note, blood pressure measurements 
taken by general practitioners that were not documented 
in the hospital notes were not accounted for in this audit. 
A good proportion (81.1%) of hypertensive patients 
were being treated with ACE inhibitors or ARBs as 
recommended. Monitoring of diabetic patients by 
measurement of HbA1c requires improvement since it 
was checked in 46.7% of diabetic patients. Control of 
diabetes in patients in whom HbA1c was checked was 
adequate.  
An improvement in the monitoring of the risk 
factors for cardiovascular disease would enable the 
calculation of the 10 year risk of fatal cardiovascular 
disease by using the SCORE chart in a larger proportion 
of patients. Hence this would enable the treatment of 
hyperlipidaemia when indicated. In fact, out of the 29 
patients in whom the cardiovascular risk could be 
calculated by using the SCORE chart, four patients who 
would benefit from treatment with a statin (and were not 
on any lipid lowering drugs) were identified. 
Monitoring of disease activity by measurement of 
ESR and CRP was adequate. However, the calculation of 
DAS28 was lacking (20.9% in a one year period; 42.9% in 
the two year period). This finding is in concordance with 
the findings of another audit where only 50% of 
patients starting treatment with a biologic agent had a 
DAS 28 score documented in the year prior to starting 
this treatment.23 This requires improvement since the 
calculation of DAS28 enables a better identification of 
patients with a high disease activity that in itself 
increases the risk for cardiovascular disease. Our results 
show that in those patients in whom DAS28 was 
calculated, 41% were in remission or had a low disease 
activity. 
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Table 1: Summary of the percentage of patients in whom risk factors and disease activity measurements have been 
measured over the period audited. 
 
Risk factor / Disease 
activity measurement 
Percentage of patients in whom 
risk factor is documented (over a 
one year period, if applicable) 
Percentage of patients in whom 
risk factor is documented over 
a two year period (if applicable) 
Weight 27.5%  
BMI 0%  
Smoking status  72.5%  
Blood pressure 53.8% 72.5% 
Blood glucose 57.1% 72.5% 
Lipid profile 38.5% 54.9% 
ESR 95.6% 100% 
CRP 92.3% 97.8% 
DAS 28 20.9% 42.9% 
 
The audit shows that ACPA was not measured or 
documented in 47.3% of rheumatoid arthritis patients. 
This requires improvement, especially in view of its 
prognostic significance.24 
Thus from our audit we can conclude that the 
management of cardiovascular risk factors is reasonable 
when these have been identified. However, a better 
cardiovascular risk assessment of the rheumatoid 
arthritis patients would enable the identification of risk 
factors that could then be treated to help decrease the 
patients’ morbidity and mortality from cardiovascular 
disease. This could be done by introducing a proforma 
(including cardiovascular risk factors and the calculation 
of the 10 year risk of fatal cardiovascular disease), that 
would be filled in on a yearly basis during the patients’ 
visit at outpatients. This would serve to remind the 
clinician of the current recommendations and ensure that 
the cardiovascular risk factors are monitored and 
documented.  
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